BridgeBio presented data from ATTRibute-CM study on acoramidis

BridgeBio (BBIO) Pharma presented data from the ATTRibute-CM study showing that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular mortality, CVM, or recurrent cardiovascular-related hospitalizations, CVH, within the first month of treatment in patients with ATTR-CM. These data were presented in a Late Breaking Clinical Trials Oral Presentation at the Heart Failure Society of America, HFSA, Annual Scientific Meeting, ASM, 2025 and simultaneously published in Journal of the American College of Cardiology. Acoramidis is a selective, small molecule, orally administered, near-complete transthyretin, TTR, stabilizer. Details from the late breaking oral presentation included: At Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo; Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction; The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants; In addition to the late breaking oral presentation, a simultaneous publication in Journal of the American College of Cardiology, with the same title as the presentation, noted the same details and also concluded that at Month 42, CVM was reduced with continuous acoramidis versus placebo-to-acoramidis with a hazard reduction of 45%